2024
Letter to the Editor
Title

Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥ 60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase

Author(s)
Heudobler, Daniel
Lüke, Florian  
Fraunhofer-Institut für Toxikologie und Experimentelle Medizin ITEM  
Hahn, Joachim
Grube, Matthias
Schlosser, Pavla
Kremers, Stephan
Südhoff, Thomas
Westermann, Jörg
Hütter-Krönke, Marie Luise
Schlenk, Richard F.
Weber, Daniela
Paschka, Peter
Zeman, Florian
Döhner, Hartmut
Herr, Wolfgang
Reichle, Albrecht
Thomas, Simone
Journal
Open Access
DOI
Additional link
Language
English